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aim of the guidelines
The aim of these guidelines is to provide practical clinical
guidance and recommendations to clinicians to manage diffuse
large B-cell lymphomas (DLBCLs) that arise in extranodal
sites. DLBCL may arise in virtually any extranodal sites, but the
majority of these are treated as the nodal counterpart, i.e. gastric
DLBCL. For the recommended treatment, the reader can refer
to the 2015 ESMO DLBCL guidelines [1]. The choice of the
entities included in these guidelines is based on the clinical need
to give recommendations for those entities which require a
specific therapeutic approach. Recommendations for primary
cutaneous DLBCL have been already reported by ESMO.
incidence and epidemiology
DLBCL is one of the most common lymphoid neoplasms, repre-
senting 30%–58% of non-Hodgkin’s lymphoma (NHL) and with a
crude incidence in Europe of 3.8/100 000/year. Despite a common
morphology characterised by the diffuse proliferation of mature
large B cells, these tumours are clinically and biologically very het-
erogeneous. Most DLBCLs originate in lymph nodes, but ≤40%
initially present in extranodal sites [2]. Differences in molecular
pathogenesis, clinical presentation and natural history indicate that
extranodal DLBCLs are distinct entities [2]. The most common
site of origin is the gastrointestinal tract, but many other organs
and tissues may be involved such as the mediastinum, testis,
central nervous system (CNS), breast and bone. Here, we provide
guidelines for the clinical management of DLBCLs arising as
primary tumours of the mediastinum, testis, CNS, breast and
bone, whereas nodal DLBCLs have been considered separately [1].
These subtypes of extranodal DLBCLs represent ∼1%–5% of all
NHLs, and this low frequency makes the analysis of disease-specif-
ic epidemiological factors difficult [3].
diagnosis and pathology/molecular
biology
The diagnosis of DLBCL should be carried out in a reference
haematopathology laboratory with expertise in morphological
interpretation and the facilities to carry out the full range of
phenotypic and molecular investigations. Details on methods
for pathological diagnosis, immunohistochemistry and molecu-
lar biology have been fully reported in ESMO guidelines for
nodal DLBCLs [1].
primary mediastinal large B-cell lymphoma
Primary mediastinal large B-cell lymphoma (PMBCL) represents
∼10% of all DLBCLs and it is more commonly seen in women in
their third to fourth decades of life [3]. These tumours derive from
a medullary thymic B cell and are composed of large cells expres-
sing pan B-cell markers, but are negative for surface Ig. The
tumour cells are usually positive for CD23, weakly positive for
CD30 and negative for CD15. BCL6, CD10 and IRF4 are expressed
in a variable number of cases. Some tumours have morphological,
phenotypic and molecular features close to nodular sclerosing
Hodgkin’s lymphoma (HL). These tumours have been included in
the World Health Organization (WHO) category of B-cell lymph-
oma as unclassifiable and with features intermediate between
DLBCL and classical HL [3]. The molecular alterations detected in
PMBCL target three major mechanisms: NFkB activation (REL†Approved by the ESMO Guidelines Committee: June 2016.
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amplification, inactivating mutations of TNFAIP3), JAK-STAT
pathway activation (inactivating mutations of SOCS1, JAK2 ampli-
fication and IL13 overexpression) and modulation of tumour cell
interactions with the microenvironment and immune system
(down-regulation of HLA class II, PDL-1 and 2 amplifications or
translocations) [4].
primary testicular lymphomas
Primary testicular lymphomas (PTLs) are mainly DLBCLs
(80%–90%) and a minority of other histological subtypes such
as plasmablastic, Burkitt’s or mantle cell lymphoma and, rarely,
low-grade follicular lymphomas (FLs) or T-cell lymphomas [5].
Some features of DLBCL (e.g. plasmacytoid differentiation,
somatic hypermutation of immunoglobulin heavy-chain genes
and higher frequency of the loss of HLA-DR and DQ expres-
sion) suggest the possibility of antigen-driven stimulation. In
addition, an altered expression of cell surface adhesion mole-
cules may explain the propensity to disseminate to extranodal
sites. Cell of origin (COO) studies show an activated B-cell
(ABC) pattern in 60%–96% of cases. Mutations of MYD88 were
found in ∼70% of PTLs, compared with <20% in patients with
nodal DLBCLs. Interestingly, 19% of these MYD88-mutated
cases also carry CD79a mutations [6]. Inactivating mutations of
B2M and rearrangements of PDL, CIITA and FOXP1 have also
been found in 2%–10% of the cases, emphasising the role of
tumour microenvironment interactions in the pathogenesis of
these tumours.
primary central nervous system lymphomas
Primary CNS lymphomas (PCNSLs) in immunocompetent
patients represent 2%–3% of all brain tumours. Most of these
cases are DLBCLs and 10%–20% develop intraocular lesions.
Extraneural dissemination is rare, but clonally related cells have
been detected in the blood of some of these patients [7].
Different studies to determine the COO have yielded inconclu-
sive results with many tumours expressing both germinal centre
(GC) markers and the ABC marker IRF4 [7]. Molecular studies
have shown activation of NFkB and BCR/MYD88 pathways and
deletions of the HLA gene locus at 6p21.32, suggesting that,
similarly to PTLs and PMBCLs, interactions with the micro-
environment are important pathogenic mechanisms [7].
MYD88 mutations have been detected in 30%–75% of cases and
CD79A/B mutations in up to 45%, with substantial overlap in
the positive cases, so that many carry both mutations [8].
primary diffuse large B-cell lymphoma of the breast
Primary breast lymphoma (PBL) is an uncommon tumour
representing <1% of NHLs and <0.5% of all breast tumours.
Histologically, these lymphomas are heterogeneous and include
DLBCLs, which are the most common form, mucosa-associated
lymphoid tissue (MALT) lymphomas, FL, Burkitt’s lymphomas
(mainly occurring during pregnancy or lactation) and anaplastic
lymphoma kinase-negative T-cell lymphomas, which are asso-
ciated with breast implants. Molecularly, primary breast DLBCLs
are mainly of ABC-subtype and cytogenetic studies have observed
trisomy 3 and 18 and chromosome 18 translocations involving
IGH/MALT1 as in low-grade MALT lymphomas [9].
primary diffuse large B-cell lymphoma of the bone
Primary bone lymphoma (PBoL) is a rare category accounting
for <1% of NHLs and ∼5% of either all primary extranodal
NHLs or all bone tumours. It is defined as a lymphoma confined
to bones and is usually radiologically evident. These tumours
may be clinically distinct from primary bone marrow lymph-
omas, in which the tumour cells are restricted to the marrow
cavity without radiological or histological evidence of cortical
bone destruction [10]. However, this distinction is challenged in
the present positron emission tomography (PET) era by the in-
creasing recognition of asymptomatic lesions with focal bone
marrow uptake, sometimes but not necessarily accompanied by
alterations of the bone tissue. They are more common in mid-
elderly men and the vast majority are DLBCLs, although other
subtypes may also rarely occur. Non-GC phenotype is slightly
more common than GC. BCL2, BCL6 and MYC rearrangements
may be found in 19%, 14% and 9% of the cases, respectively.
There is insufficient literature and too few reported patient out-
comes to enable firm conclusions regarding the prognostic
impact of the COO.
staging and risk assessment
Baseline assessments and procedures do not generally differ
from those required for patients presenting with nodal DLBCLs
and include: physical exam, determination of performance
status (PS), B symptom assessment, complete blood count,
routine blood chemistry with lactate dehydrogenase (LDH) and
screening tests for human immunodeficiency virus and hepatitis
B and C (Table 1).
Based on the new consensus recommendations for staging
and restaging of lymphoma developed by the clinical and
imaging working groups of the International Conference on
Malignant Lymphomas, fluorodeoxyglucose positron emission
tomography/computed tomography (FDG-PET/CT) scan is
now recommended as standard practice both for staging
patients with DLBCL and for response assessment based on the
visual Deauville criteria (five-point scale, Table 2) [11].
Additional and specific staging procedures are reported in
each section for different extranodal sites and are summarised in
Table 1.
The disease staging is established as nodal DLBCL according to
the Ann Arbor classification system (Table 3). In extranodal
DLBCL, the discriminating utility of the International Prognostic
Index (IPI) and age-adapted IPI (aaIPI) is not fully evaluated;
however, these tools should be calculated for prognostic purposes
at least to differentiate between localised versus advanced stage
disease [II, A] (Table 4). Specific risk score models have been devel-
oped by the International Extranodal Study Group (IELSG) for
PCNSL and PBoL; they are described in each related paragraph
below and are summarised in Table 5 [12] and Table 6 [13].
treatment
The treatment and recommendations for each entity are detailed
separately in each section. The International Lymphoma Radiation
Oncology Group have recently published comprehensive guide-
lines on the use of radiotherapy (RT) in extranodal lymphomas,
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and these guidelines should be referenced in every section regard-
ing the detailed techniques and dose requirements [14].
primary mediastinal large B-cell lymphomas
PMBCLs usually present with a bulky tumour in the anterior
mediastinum, with local compressive symptoms including dys-
pnoea, cough, dysphagia and a superior vena cava syndrome in
∼50% of cases. Pleural or pericardial effusions are often present.
Particular extranodal sites such as kidneys, adrenal glands, liver
and ovaries may be involved, particularly in the setting of
disease recurrence. For prognostic characterisation, the IPI
remains the standard score, but its discriminatory utility in
PMBCL is limited by the age distribution of the disease and its
usual confinement to the mediastinum.
FDG-PET/CT scan is mandatory to assess disease extent and
to obtain better definition of the residual mediastinal masses at
the completion of treatment, because PMBCL shows universal
avidity for [18F]-2-fluoro-2-deoxyglucose.
treatment. The combination of rituximab with cyclophosphamide,
doxorubicin, vincristine and prednisolone (R-CHOP) or with
VACOP-B (etoposide, doxorubicin, cyclophosphamide, vincristine,
prednisolone and bleomycin)/MACOP-B (methotrexate,
Table 1. Summary of diagnostic work-up
Diagnostic work-up for all entities
Physical examination Peripheral lymph nodes, liver, spleen
Laboratory Blood cell and differential count, renal and liver function, LDH, uric acid
Serology Hepatitis B (including HBsAg, anti-HBs and anti-HBc antibodies) and C, HIV
serology
Imaging CT neck, chest, abdomen and pelvis, PET/CT
Bone marrow Histology
Additional diagnostic work-up for specific entity PTL PCNSL PBL PBoL
Brain MRI Yes Yes Yes Noa
Cytology and flow cytometry of cerebral spinal fluid Yes Yes Yes Noa
Testicular ultrasound Yes Elderly males yes No No
Ocular slit-lamp examination No Yes No No
Involved MRI of bone lesion No No No Yes
LDH, lactate dehydrogenase; HIV, human immunodeficiency virus; CT, computed tomography; PET/CT, positron emission tomography/computed
tomography; PTL, primary testicular lymphoma; PCNSL, primary central nervous system lymphoma; PBL, primary breast lymphoma; PBoL, primary bone
lymphoma; MRI, magnetic resonance imaging.
aOnly if involvement of skull and/or spine.
Table 2. Positron emission tomography (PET) five-point scale
(Deauville criteria)
1 No uptake
2 Uptake ≤mediastinum
3 Uptake >mediastinum but ≤liver
4 Moderately increased uptake compared with liver
5 Markedly increased uptake to liver and/or new lesions
Table 3. Ann Arbor staging classification
Stage
I Involvement of a single lymphatic region (I) or localised
involvement of single extralymphatic organ or site (IE)
II Involvement of two or more lymphatic regions on the same side
of the diaphragm (II) or localised involvement of a single
extralymphatic organ or site and of one or more lymphatic
regions on the same side of the diaphragm (IIE)
III Involvement of lymphatic regions on both sides of the
diaphragm
IV Diffuse or disseminated involvement of one or more
extralymphatic organs with or without lymphatic involvement
Table 4. International prognostic index (IPI)
International prognostic index—IPI
Risk factors Age >60 years
Serum LDH > normal
Stage III–IV
PS 2–4
Extranodal sites >1
Risk categories Low 0–1
Low intermediate 2
High intermediate 3
High 4–5
Age-adjusted international prognostic index—aaIPI—in patients ≤60 years
Risk factors Serum LDH > normal
Stage III–IV
PS 2–4
Risk categories Low 0
Low intermediate 1
High intermediate 2
High 3
LDH, lactate dehydrogenase; PS, performance status.
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doxorubicin, cyclophosphamide, vincristine, prednisolone and
bleomycin) (R-V/MACOP-B), dose-dense CHOP (R-CHOP14) or
more intensive chemotherapy regimens such as DA-EPOCH-R
(dose-adjusted etoposide, prednisone, vincristine
cyclophosphamide, doxorubicin and rituximab) are the current
standard treatments for PMBCLs and any of them can be used
according to the centre’s experience [III, A] [15, 16].
Consolidative mediastinal RT is recommended in responding
patients treated with standard-dose chemoimmunotherapy (R-
CHOP/R-V/MACOP-B) [II, A] [16].
Based on the results of a small phase II study, consolidative medi-
astinal RT could be omitted in patients with a complete metabolic
response (CMR) only after DA-EPOCH-R [III, C] [15]. However,
these results need to be validated in a larger, multicentre series.
Where used, consolidative mediastinal RT should be adminis-
tered with doses in the range 30–36 Gy, in 1.5–2.0 Gy fractions
[II, A].
The role of consolidative mediastinal RT in the 50% of patients
with CMR (PET/CT negative) post-chemoimmunotherapy is cur-
rently being investigated. The results of the ongoing comparative
randomised trial (IELSG-37) (NCT01599559) will determine
whether consolidative RT could be omitted in patients with a
CMR at the post-chemoimmunotherapy PET/CT scan following
R-CHOP-like regimens. Outside of a clinical trial, there are in-
sufficient data to support omission, especially as relapses are dif-
ficult to salvage with poor outcomes.
Based on the good results achieved with rituximab chemo-
therapy combination regimens ± RT, high-dose chemotherapy
followed by autologous stem cell transplantation (HDCT/
ASCT) is not recommended in patients who achieved complete
remission (CR), even in initially poor-risk patients who attain
an adequate response to initial therapy [III, A].
In young patients who do not obtain an adequate response
(i.e. less than partial response) with an elevated FDG uptake at
the post-chemoimmunotherapy PET/CT scan, if residual
disease is confirmed by biopsy when feasible, an intensification
therapy with HDCT/ASCT is recommended [III, B].
post-treatment evaluation. A PET/CT scan in PMBCL has an
excellent negative predictive value, but it also has a low positive
predictive value due to the high frequency of false-positive
scans. Thus, positive PET scans require further investigation
before modifying planned therapy. Several patients with
persistent metabolically active masses underwent biopsies,
which showed necrosis but no lymphoma. False increased FDG
uptake may be due to an inflammatory response produced
by the addition of rituximab to chemotherapy or a thymic
rebound, which is particularly relevant, given the location of the
disease [17]. Thus, positive PET scans require further investigation
before modifying planned therapy. A post-treatment PET/CT
response evaluation should not be carried out until at least 5–6
weeks from the last infusion of chemotherapy to minimise the
incidence of these false-positive scans. Serial scanning may be
required to fully evaluate areas of residual post-treatment PET
tracer uptake, with many patients manifesting gradual resolution.
treatment of relapsed/refractory PMBCL. The probability of
recurrence after successful initial therapy for PMBCL appears to
be lower than for other DLBCLs, and those patients who achieve
a response lasting longer than 18 months are likely to be cured.
Salvage treatment strategies of relapsed/resistant patients are
similar to nodal DLBCLs, and include attempting reinduction
with non-cross-resistant agents followed by consolidation with
HDCT/ASCT in patients with chemosensitive disease [II, A].
If radiation has not been a component of initial therapy, RT
should be incorporated into the salvage treatment programme
for patients with relapsed disease, ideally post-transplant if sig-
nificant mediastinal or lung volumes are involved.
primary testicular lymphomas
PTLs usually present as a limited stage disease with most patients
having a unilateral testicular mass, although bilateral testicular in-
volvement occurs in ∼10%. There is a propensity for an aggres-
sive clinical behaviour with dissemination to multiple extranodal
sites, such as lung, pleura, skin (up to 35%), soft tissues and
Table 5. The International Extranodal Lymphoma Study Group
(IELSG) prognostic score for PCNSL
Variable Favourable feature
(value ‘0’)
Unfavourable feature
(value ‘1’)
Age (years) <60 >60
ECOG PS score 0–1 >1
Lactate dehydrogenase
serum level
Normal Elevated
Cerebrospinal fluid
protein level
Normal Elevated
Involvement of deep
regions of the CNSa
No Yes
IELSG score 0–1, low risk; 2–3, intermediate risk; 4–5, high risk.
PCNSL, primary central nervous system lymphoma; ECOG PS, Eastern
Cooperative Oncology Group performance status; CNS, central nervous
system.
Reprinted from [12] with permission. @2003 American Society of
Clinical Oncology. All rights reserved.
aDeep regions include the corpus callosum, basal ganglia, brain stem and
cerebellum.
Table 6. The International Extranodal Lymphoma Study Group
(IELSG) staging system for DLBCL of the bone
Lymphoma extension IELSG
Stage
Single bony lesion IE
Single bony lesion with involvement of regional lymph
nodes
IIE
Multifocal disease in a single bone or lesions in multiple
bones in a disease exclusively limited to the skeleton
(without lymph nodal or visceral disease)a
IVE
Disseminated lymphoma with at least one bony lesion IV
Reprinted from [13], with permission from Elsevier.
aAlso calledmultifocal osteolymphoma or polyostotic lymphoma.
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Waldeyer’s ring (5%). CNS relapses are frequent and occur in up
to 30% of PTL patients within 1–2 years of diagnosis, but can
also be delayed in presentation [18]. For staging, in addition to
the standard tests, ultrasound of the contralateral testis, brain
nuclear magnetic resonance imaging (MRI) and diagnostic
lumbar puncture with cytological and flow cytometric analysis on
cerebrospinal fluid (CSF) are mandatory. Orchiectomy remains a
mandatory step in the management of PTL, both for diagnostic
and for therapeutic aims [III, A] [19].
treatment. In the IELSG retrospective series, chemotherapy
with anthracycline-containing regimens significantly improved
the outcome in all patients [19]. Despite the lack of randomised
studies, some retrospective studies and a prospective one
(IELSG10) provided evidence of the benefit of the addition of
rituximab to chemotherapy [20]. Six to eight cycles of R-CHOP
given every 21 days is the current standard [II, A].
If orchiectomy is not carried out, RT is given to the involved
testis. The addition of RT to the contralateral testis significantly
reduces or abrogates testicular relapses in retrospective and pro-
spective studies [19–21]. Hence, prophylactic RT to the contra-
lateral testis and scrotum is strongly recommended [III, A]. The
dose to the testis should be 25–30 Gy in 1.5–2 Gy fractions.
Such treatment to the remaining testis is associated with a sub-
stantial risk of hypogonadism; therefore, sequential monitoring
of testosterone levels and replacement therapy are clinically im-
portant and should be included in the follow-up programme for
these patients. RT was given in the past to involved abdomino-
pelvic nodes in stage IIE disease; however, the lack of well-
conducted trials makes it difficult to assess the role of nodal RT
in this setting. Indeed, also in nodal DLBCL, with the introduc-
tion of PET reassessment after R-CHOP, consolidation RT is
less frequently used in patients who achieved a PET-negative
CR. Based on these indirect data and considering the increased
toxicity, RT to involved nodes could be safely omitted if PET
negative after R-CHOP chemotherapy [III, C], as in the ongoing
IELSG30 phase II study (NCT00945724).
Although some conflicting data exist, a prophylactic therapy to
reduce the risk of CNS relapse should be added to the treatment
[III, B]. Two options can be considered: intrathecal chemotherapy
with methotrexate (MTX) is the most common one; alternatively,
intravenous systemic MTX can be employed as part of overall treat-
ment [III, B] [5]. The best strategy to further reduce CNS recurrence
remains an open issue. The ongoing IELSG30 phase II study that
includes both intrathecal chemotherapy with liposomal cytarabine
and systemic prophylaxis with a lower dose of MTX (1.5 g/m2) to
spare toxicity in elderly PTL patients aims at addressing this issue.
In summary, the recommended treatment for stage I–II PTL
consists of R-CHOP21 × 6–8 courses, with the addition of CNS
prophylaxis and prophylactic RT to the contralateral testis.
The therapy of advanced-stage PTLs is not different from the
standard treatment of advanced-stage nodal DLBCLs. Unlike
nodal DLBCLs, two treatment issues should be incorporated in
the therapeutic strategy: prophylactic testicular RT and CNS
prophylaxis [18].
post-treatment evaluation. As in nodal DLBCLs, FDG-PET/CT
can be considered the recommended standard for post-treatment
assessment in PTL.
treatment of relapsed/refractory PTL. Standard therapeutic
option for these patients has not yet been defined in prospective
trials. HDCT/ASCT, if feasible, should be the preferred treatment
strategy in chemosensitive relapse as in nodal DLBCL [I, A] [22].
However, many PTL patients are elderly, with poor PS and multi-
organ dysfunction; the inclusion of these patients in clinical trials
testing novel drugs is advisable.
primary CNS lymphomas
PCNSLs are rare diseases defined by involvement of the cerebral
parenchyma, leptomeninges, eyes or spinal cord without evi-
dence of systemic disease.
Patients with PCNSL usually present with focal neurological
deficits and/or neuropsychiatric symptoms. Symptoms of
increased intracranial pressure and seizures are less frequent
[12]. Approximately 10%–20% of patients have ocular involve-
ment, with floaters, blurred vision, diminished visual acuity and
painful red eyes. About one-third of patients present with multi-
focal neurological disease, with highly diverse deficits.
Stereotactic biopsy is recommended as a minimal invasive
technique to obtain histopathological diagnosis [III, A]; therefore,
resection of PCNSL cannot be recommended, because of the
associated morbidity and lack of evidence for benefit [23].
Glucocorticoid therapy can interfere with an accurate histopatho-
logical diagnosis; therefore, it should be avoided before biopsy if
possible without clinically compromising the patient [24].
At diagnosis, patients should undergo contrast-enhanced brain
MRI as the standard for baseline and response assessment, as
well as cytological evaluation and flow cytometry of the CSF. In
addition, slit-lamp examination should be carried out to investi-
gate possible ocular involvement. CT scans of the chest, abdomen
and pelvis or a PET/CT scan is carried out to exclude systemic
disease. Additionally, testicular ultrasound examination in elderly
male patients is recommended [V, B] [23]. In PCNSL, the value
of a bone marrow examination is controversial; however, it is still
part of baseline investigations in current PCNSL trials.
The IELSG has proposed a prognostic system for PCNSL
based on the following independent prognostic factors: age >60
years, Eastern Cooperative Oncology Group (ECOG) PS >1,
elevated serum LDH, elevated CSF protein concentration
and tumour localisation within the deep regions of the brain.
Three risk classes are defined for patients with 0–1 (good-risk),
2–3 (intermediate-risk) or 4–5 (poor-risk) prognostic factors
(Table 5) [12]. Another validated risk score developed by Abrey
et al. [25] only requires age and clinical PS to build three differ-
ent risk groups good risk (patients <50 years), intermediate risk
(patients ≥50 years and Karnofsky performance score [KPS]
≥70) and high risk (patients ≥50; KPS <70).
first-line treatment. Historically, whole-brain radiotherapy
(WBRT) has been the standard treatment for PCNSL. Despite
the high CR rate, the disease relapses in almost all patients after
a few months, with a median survival of 12 months and few
long-term survivors. The addition of chemotherapy to WBRT
has been recommended to improve survival of PCNSL patients.
High-dose MTX (HD-MTX; at least 3 g/m² over 2–4 hours
rapid infusion time) is considered the most effective single agent
for treating PCNSL [25]; however, based on prospective studies,
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CR rates are usually <30% with single-agent, high-dose MTX.
The addition of high-dose cytarabine (HD-ara-C) has been
shown to significantly improve response rate (RR) and failure-
free survival, compared with high-dose MTX alone in a phase II
randomised trial [26]. Other CHOP-like protocols were asso-
ciated with unsatisfactory results in PCNSL [26]. Several single-
arm studies have investigated other drugs in combination with
HD-MTX without clear additional benefit, including ifosfamide,
thiotepa, procarbazine, vincristine and temozolomide [27].
The role of prophylactic intrathecal chemotherapy is unclear.
Retrospective studies do not suggest a benefit from adding intra-
thecal chemotherapy combined to systemic high-dose MTX. On
the other hand, other non-randomised studies suggested that
intraventricular treatment combined with an MTX-based chemo-
therapy was effective in reducing relapse rate [28]. Thus, the ef-
fectiveness of intrathecal therapy is contradictory and may
different according to the route of administration. In summary,
intrathecal chemotherapy cannot be routinely recommended
if appropriate systemic chemotherapy is applied, but could be
considered in the case of severe meningeal involvement [IV, C]
[24, 29].
RT with doses between 40 and 45 Gy in 20–25 fractions is pri-
marily used as consolidative therapy following HD-MTX-based
chemotherapy. Higher RT doses following chemotherapy are
associated with an increased risk of neurotoxicity, which is par-
ticularly pronounced in the older age group (30% of all patients
and 40%–50% of those >60 years of age). This neurotoxicity led
to testing lower RT doses, as low as 30–36 Gy for WBRT or
23.4 Gy after chemotherapy-induced CR [27]. These regimens
appeared to be effective and without prohibitive RT-related tox-
icity, even in elderly patients [27, 29–31].
HDCT/ASCT represents an alternative strategy for consolida-
tion treatment aimed at sparing neurotoxicity, avoiding RT and
improving outcome. HDCT/ASCT has been used as part of
front-line treatment in PCNSL patients with encouraging
results, mostly using thiotepa-based conditioning regimens with
overall remission rates of up to 91% and a 5-year overall survival
(OS) of 87% for those who completed HDCT [32]. Another ap-
proach to avoid WBRT is consolidation with dose-intensive
conventional chemotherapy, such as etoposide and ara-C after
HD-MTX-based induction [24].
Recently, the preliminary results of IELSG32 randomised
study (NCT01011920, Eudra CT number 2009-014722-42) sug-
gested a benefit of the addition of rituximab and thiotepa in
newly diagnosed PCNSL with regard to RR, progression-free
survival (PFS) and OS [33]. This is also supported by retrospective
series investigating combination of rituximab with HD-MTX.
elderly patients (age >70 years or patients with comorbidities).
Selected elderly patients are often able to tolerate HD-MTX-
based treatment, with dosage guided by renal function [24].
Based on a recent systematic review and individual patient data
meta-analysis, HD-MTX-based treatment was associated with
an improved survival outcome [34]. Further combinations with
oral alkylating agents such as lomustine (CCNU) and
procarbazine ± vincristine are feasible, active and are warranted
to be compared with HD MTX alone [31, 35]. Overall, HD
MTX-based treatment should be considered whenever possible
in elderly patients with PCNSL [II, A]. WBRT should not be a
routine component of front-line therapy in elderly patients able
to tolerate other therapies, due to its high rate of neurotoxicity,
and is reserved for frail patients or patients with refractory
disease [14].
In summary, HD-MTX-based regimens, in combination with
HD-ara-C, are recommended for induction treatment if possible
based on patient age, PS and organ function [I, A]. HD-MTX-
based treatment should be considered whenever possible in
elderly patients with PCNSL [II, A].
The use of WBRT as consolidation after HD-MTX-based
chemotherapy is still commonly applied in young patients and
generally avoided in those >60 years, as the risk of neurotoxicity
(including cognitive deterioration) is particularly high in elderly
patients [III, B].
Thus, we recommend that consolidation RT should be
avoided in elderly patients who achieved CR [III, B], while in
those not reaching CR, it is preferable to use lower doses of
WBRT (36 or 23.4 Gy) based on response [III, B].
Whether RT can safely be omitted without compromising
long-term outcome also in younger patients in CR remains con-
troversial [III, C]. HDCT/ASCT as consolidation treatment
could be considered as an alternative to WBRT in eligible
patients [III, B].
post-treatment evaluation. Brain MRI is the standard for
response evaluation. For patients with previous CSF involvement,
CSF analysis (cytology and flow cytometry) should be added, as
well as spinal imaging as clinically indicated. In the follow-up,
brain MRI monitoring may be helpful to rule out progression,
but the overall clinical utility of such a surveillance strategy is
unproven. For patients with prior CSF or ocular involvement,
specific assessments (i.e. CSF evaluation or ophthalmologic
evaluation) are needed as clinically indicated. Based on the rarity
of systemic progressions, additional systemic evaluation (i.e. CT
or CT/PET scans) are indicated only in the case of clinical signs
or symptoms of systemic progression.
treatment of relapsed/refractory PCNSL. HDCT/ASCT has
been prospectively investigated in patients with disease relapse
after HD-MTX with a median survival of 18.3 months (58.6
months for those who received HDCT/ASCT) [36]. Only a few
agents have been investigated prospectively in the relapse/
refractory setting, namely temozolomide [36], temozolomide
plus rituximab [37], topotecan and pemetrexed. However, none
of these showed convincing activity sufficient to be established
as standard in this situation. Re-exposure to the same HD-
MTX-based protocol can be considered; however, there are no
data on the relationship between efficacy and the duration of
prior response. When RT is used as a single modality therapy, i.e.
WBRT as primary treatment for non-candidates for chemotherapy,
higher doses (40–50 Gy, 1.5–1.8 Gy/fraction) are required. Doses of
36 Gy have been shown to be beneficial in a salvage setting, but the
optimal dose and the role of boost doses remain uncertain [38].
In summary, choice of salvage treatments depends on the
clinical status, toxicities from previous treatments and duration
of remission. Based on the limited evidence available so far, no
standard protocol can be recommended. Fit patients should
be considered for HDCT/ASCT [III, B]. WBRT remains an im-
portant palliative treatment in PCNSL lymphoma for those
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unable to tolerate or relapsing after high-dose, CNS-penetrating
chemotherapy and not fit for further chemotherapy [III, B].
primary breast lymphoma
PBL is typically a disease of older women (median age 62–64
years), but with lower median ages in specific geographic areas
(i.e. in East Asian countries) [39, 40]. PBL almost exclusively
affects women, with very rare male cases reported, but with
apparently similar outcomes [41]. The typical presentation is a
painless breast mass (median 4 cm diameter), slightly more fre-
quently on the right side and with systemic symptoms present
in <5% of patients, almost always those with disseminated
disease [42].
Currently, up to 20% of patients are diagnosed incidentally
[42, 43], but there are no definitive radiologic features of PBL;
therefore, a diagnostic biopsy is mandatory [IV, A].
The specific additional staging procedures recommended for
PBL include contralateral breast examination for potential bilat-
eral involvement, which would usually be dealt with adequately
by whole-body PET/CT. CNS imaging with MRI of the brain
and CSF analysis by cytology and flow cytometry should also
be carried out even in the absence of CNS symptoms [IV, B].
Approximately 70% of patients have stage IE disease, with the
other 30% having regional nodal involvement (stage IIE) [41].
From 4% to 13% of patients have bilateral breast involvement at
presentation [41].
The standard IPI is predictive of outcome, but this has low
discriminatory ability, while the stage-modified IPI has a better
prognostic discrimination, mainly through the adverse impact
of stage IIE disease [41, 44]. Other reproducible adverse prog-
nostic factors among patients with localised disease include
tumour size >4–5 cm [44, 45] and bilateral involvement that
was found to be a significant adverse predictor of both PFS and
OS, with a high risk of CNS relapse [41, 43].
Reminiscent of PTL, PBL displays extranodal tropism at
relapse [46]. The ipsilateral and contralateral breasts were
involved at relapse in 12%–44% of series with available data
[40], with ipsilateral breast relapse occurring in the first few
years following treatment, while in contrast, contralateral breast
relapse occurred up to 13.3 years later [41]. Other extranodal
sites including the bone marrow, lung or pleura, skin, gastro-
intestinal tract and CNS have all been reported to occur more
commonly in PBL than among nodal DLBCLs [39, 44].
From larger series, CNS relapse developed in 5%–16% of
patients, with a weighted average of ∼12%. Other than poten-
tially bilateral disease, there are no reproducible predictors of
CNS relapse risk.
treatment. Surgical resection as a sole modality results in
inadequate local control, and the application of mastectomy is
associated with inferior outcomes [41, 44]. In the rare instance
of patients who have undergone surgical excision, they should
still be managed identically as recommended below [V, B].
The retrospective IELSG-15 study reinforced the importance
of an anthracycline-containing chemotherapy regimen with a
strongly favourable impact on both PFS and OS. Most recent
contemporary series have used CHOP ± rituximab and RT with
5-year PFS and OS of 50%–70% [41, 42, 47]. In cohorts without
stratification by risk, abbreviating the number of chemotherapy
cycles to fewer than 4 has resulted in inferior outcomes [39, 41].
Although there are no randomised studies addressing the ques-
tion, most historical comparisons suggest some favourable
impact from the incorporation of rituximab, and given its estab-
lished role in DLBCL treatment, it should be routinely included
in front-line chemoimmunotherapy as part of R-CHOP q 21d
[III, B]. There are no data supporting the use of more aggressive
or dose-escalated regimens as part of primary therapy [III, B].
Whole-breast RT is generally recommended after chemother-
apy based on the benefit in OS observed in the large IESLG
study [41], but some experts consider partial breast RT in cases
where the resulting morbidity reduction is likely to offset the po-
tential increase in marginal relapse rate, especially where PET
scanning has been used in initial staging to allow accurate delin-
eation of the involved area and nodal status [14]. The unin-
volved lymph nodes need not be included in the RT volume,
provided initial staging has used PET [14].
treatment recommendations. The recommended treatment for
PBL is as follows: 6 cycles of R-CHOP, if therapy is well
tolerated [III, A], followed by consolidative whole ipsilateral
breast RT (30–36 Gy) [III, B]. CNS-directed prophylaxis
should be considered for individual patients [III, B], and is
recommended in high-risk patients, i.e. bilateral involvement [III,
A]. No specific CNS prophylaxis treatment can be recommended
due to the lack of data; in nodal DLBCL, either intrathecal or i.v.
MTX could be appropriate [48]. Patients with bilateral breast
involvement represent a particularly high-risk group, and
investigation of more intensive chemotherapy regimens in the
context of clinical trials is justified in such cases [IV, C].
post-treatment evaluation. As in nodal DLBCL, FDG PET/CT
can be considered the recommended standard for post-treatment
assessment in PBL (Table 2). The Lugano 2014 criteria are also
applied to PBL.
treatment of relapsed/refractory PBL. The outcome of patients
after relapse is poor; in the IELSG-15 series, the median survival
after relapse was 1.0 year, with a 5-year OS of 20% [41]. The
management strategy should be as per other instances of
relapsed DLBCL, with reinduction chemoimmunotherapy
aiming to proceed to HDCT/ASCT, where feasible, in patients
with responsive disease [IV, B].
primary bone lymphoma
PBoL may present as a single bone lesion with or without an
associated soft tissue mass arising from local extension and with
or without regional lymphadenopathy or as a multifocal polyos-
totic disease exclusively involving the skeleton [13].
The median age at diagnosis varies from 45 to 60 years.
Patients with PBoL typically present with bone pain (80%–
95%), a tumour mass in 30%–40% of the cases and pathological
fracture, most frequently of the humerus, in 10%–15% of
patients. Approximately 15% of patients show spinal cord com-
pression and 10% have hypercalcaemia, usually in the presence
of rapidly progressive disease. The femur, the pelvic bones and
the spine are the most common sites of involvement [13, 49].
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Most patients have early-stage disease at diagnosis [13], and
PET/CT has increased the detection of asymptomatic bone lesions
as part of the initial presentation of disseminated DLBCL [49]. In
comparison with CT scan, MRI better defines the local extent of
the disease and cortical changes. An adapted staging system for
PBoL has been proposed by the IELSG (Table 6) [13, 50].
The prognosis of primary bone DLBCLs mainly depends on
the disease extent: 5-year OS rates vary from >80% for stage IE
to <40% for disseminated DLBCL with bone localisation [51].
The role of the IPI in predicting prognosis of primary DLBCL of
the bone seems limited [13, 49, 51].
treatment. Primary bone DLBCL should be treated with
anthracycline-containing chemotherapy regimens together with
rituximab, although the benefit of the addition of rituximab has
not formally studied specifically in the subset of patients with
PBoL. The role of consolidation RT is not well defined because
the available data are very controversial and mainly come from
retrospective analyses that suggest benefit [51, 52]. Indeed, R-
CHOP ± consolidation RT remains the standard approach for
the patients with any stage of DLBCL with bone involvement
[III, B]. Whether RT to sites of bone involvement is truly
needed or can be spared (at least in cases with a negative PET
scan after chemoimmunotherapy) should be addressed in
appropriately designed prospective randomised trials [51].
When consolidation RT is given to localised lesions, there is
limited additional benefit from the use of extensive radiation
volumes and RT and dose range is 30–40 Gy, depending on the
certainty that a CR has been obtained with chemotherapy [13].
The risk of CNS recurrence associated with skeletal involve-
ment is also a matter of debate [13]. In the IELSG-14 study, con-
ducted in the pre-rituximab era, CNS involvement (mainly
meningeal) occurred in 2.5% of patients with localised primary
bone DLBCL [51]. Hence, CNS prophylaxis is not routinely
required in these patients [III, B]. However, an accurate assess-
ment (CSF flow cytometry and brain MRI) and prophylaxis can
be recommended in patients with involvement of anatomic
areas in close apposition to the CNS (skull and/or spine) [III,
B]. CNS recurrence occurs in 7% of these patients, particularly
those with disseminated DLBCL and other high-risk features,
and decisions regarding CNS prophylaxis should be made on
the basis of established risk profiling [48].
The presence of pathological fracture at presentation is asso-
ciated with an inferior outcome in PBoL in the IELSG14 study
[49]. The initial surgical stabilisation of the pathological fracture
should be directed at achieving a better quality of life (e.g.
control pain, prevent bone displacement, allow weight-bearing);
however, there is no evidence that initial surgical stabilisation
improves the lymphoma outcome, with a 5-year OS of 45% and
54%, respectively, for patients who either did or did not receive
surgery. These data suggest that initial surgery should be consid-
ered only if chemotherapy delays can be avoided [IV, C] [49].
Patients with a pathological fracture should be initially
managed similarly to standard PBoL. Consolidation RT (30–40
Gy) to the fractured bone may be given [IV, C]. Indeed, the
initial RT of a fractured bone before chemotherapy does not
seem to improve disease control or OS when compared with the
chemoradiotherapy sequence but may improve pain and poten-
tially hasten healing [13].
response assessment and post-treatment evaluation. Post-
treatment evaluation is difficult because bone lesions remain
detectable upon CT scan. PET scan is mandatory in response
assessment as in nodal DLBCL; however, residual PET uptake
can persist and may resolve slowly, representing bone healing
rather than active disease. New treatments such as HDCT/ASCT
or alternative chemoimmunotherapy are only recommended in
the case of biopsy-proven persisting disease or clear clinical or
radiological progression [III, A].
Finally, long-term bone health preventive measures should
also be taken into account in patients with PBoL, including
evaluation and treatment of any underlying osteoporosis, and/
or vitamin D deficiency.
follow-up
Follow-up monitoring is not different from that of nodal
DLBCL [1].
personalised medicine
There are still many open issues in the treatment of extranodal
DLBCL. New agents targeting distinct molecular pathways
involved in disease pathogenesis are in progress and are being
tested in ongoing trials. So far, none of these agents is appropri-
ate for standard clinical practice.
For instance, in PMBCLs based on some molecular alterations
detected such as JAK-STAT pathway activation and modulation
of tumour cell interactions with the microenvironment and
immune system, the role of biological drugs targeting selective
pathways as JAK-STAT and PDL1, PDL2 should be evaluated.
PTLs are predominantly of ABC subtype, and lenalidomide
and ibrutinib, which preferentially target this DLBCL subtype
and have been proved to be effective in nodal ABC DLBCL, may
be tested in PTL patients in an effort to improve their outcome
[53, 54]. Moreover, both PTLs and PCNSL show a high fre-
quency of MYD88 and CD79a mutations [6] and ibrutinib that
targets this pathway may be active in these patients. Recently,
ibrutinib was reported to cross the blood–brain barrier and have
potential activity in PCNSL.
methodology
These clinical practice guidelines were developed in accordance
with the ESMO standard operating procedures for clinical
practice guidelines development, www.esmo.org/Guidelines/
ESMO-Guidelines-Methodology. The relevant literature has
been selected by the expert authors. A summary of common
and specific diagnostic procedures for each extranodal DLBCL
type is shown in Table 1. Table 7 summarises the recommenda-
tions for first-line treatment. A summary of recommendations is
shown in Table 8. Levels of evidence and grades of recommen-
dation have been applied using the system shown in Table 9.
Statements without grading were considered justified standard
clinical practice by the experts and the ESMO faculty. This
manuscript has been subjected to an anonymous peer review
process.
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Table 7. Recommended first-line treatment strategies in extranodal diffuse large B-cell lymphoma (DLBCL)
Primary sites Treatment Consolidation CNS prophylaxis
Primary testicular
lymphoma
R-CHOP21X6-8 RT to contralateral testis (25–30 Gy) IT MTX or i.v. systemic
MTX
Primary central
nervous lymphoma
HD-MTX (MTX≥ 3 g/m2) plus HD-ara-C
HD-MTX-based (adjusted dose on ECOG
PS, renal function, etc.) in elderly patients
WBRT is not routinely recommended
HDCT/ASCT suggested in young patients
(clinical trial)
N/A
Primary mediastinal
lymphoma
R-CHOP or R-V/MACOP-B or R-CHOP14
or DA-EPOCH-R
Mediastinal RT (30 Gy) in responding patients; RT
could be omitted in CMR only after DA-EPOCH-R
HDCT/ASCT is not recommended in CR1
Not recommended
Primary breast
lymphoma
R-CHOP21X6 Whole ipsilateral breast RT (30–36 Gy). Partial
breast RT in selected cases (see text)
To be considered in all
patients
Mandatory in high risk
Primary bone
lymphoma
R-CHOP21X6-8
RT before chemotherapy is not
recommended
RT (30–40 Gy) to involved bone Only if involvement of the
skull and/or spine
CNS, central nervous system; R-CHOP21, cyclophosphamide, doxorubicin, vincristine and prednisone treatment combined with rituximab given every 21
days; RT, radiotherapy; IT, intrathecal; MTX, methotrexate; i.v., intravenous; HD-MTX, high-dose methotrexate; HD-ara-C, high-dose cytarabine; ECOG
PS, Eastern Cooperative Oncology Group performance status; WBRT, whole-brain radiotherapy; HDCT/ASCT, high-dose chemotherapy followed by
autologous stem cell transplantation; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-V/MACOP-B, rituximab,
etoposide, doxorubicin, cyclophosphamide, vincristine, prednisolone, bleomycin)/rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine,
prednisolone, bleomycin; R-CHOP14, cyclophosphamide, doxorubicin, vincristine and prednisone treatment combined with rituximab given every 14
days; DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine cyclophosphamide, doxorubicin and rituximab; CMR, complete metabolic response;
CR1, first complete remission.
Table 8. Summary of recommendations
The disease staging is established as nodal DLBCL according to the Ann Arbor system. In extranodal DLBCL, the discriminating utility of the IPI and aaIPI
is not fully evaluated; however, they should be calculated for prognostic purposes at least to differentiate between localised versus advanced stage disease
[II, A]
PMBCLs
• R-CHOP, R-VACOP-B, V-MACOP-B, R-CHOP14 or more intensive chemotherapy regimens such as DA-EPOCH-R should be considered the current
standard treatment for PMBCLs; any of them can be used according to the centre’s experience [III, A]
• Consolidative mediastinal RT is recommended in responding patients treated with standard dose chemoimmunotherapy (R-CHOP/R-V/MACOP-B)
[II, A]
• Consolidative mediastinal RT could be omitted in patients with a CMR only after DA-EPOCH-R [III, C]
• Where used, consolidative mediastinal RT should be administered with doses in the range 30–36 Gy, in 1.5–2.0 Gy fractions [II, A]
• HDCT/ASCT is not recommended in patients who achieved CR, even in initially poor-risk patients who attain an adequate response to initial therapy
[III, A]
• In young patients who do not obtain an adequate response (i.e. less than partial response) with an elevated FDG uptake at the post-
chemoimmunotherapy PET/CT scan, if residual disease is confirmed by biopsy when feasible, an intensification therapy with HDCT/ASCT is
recommended [III, B]
• Salvage treatment strategies of relapsed/resistant patients include attempting reinduction with non-cross-resistant agents followed by consolidation with
HDCT/ASCT in patients with chemosensitive disease [II, A]
PTLs
• Orchiectomy remains a mandatory step for diagnostic and therapeutic aims [III, A]
• Six to eight cycles of R-CHOP given every 21 days is the current standard [II, A]
• Prophylactic RT to the contralateral testis and scrotum is strongly recommended [III, A]
• RT to involved nodes could be safely omitted if PET is negative after R-CHOP chemotherapy [III, C]
• A prophylactic therapy to reduce the risk of CNS relapse such as intrathecal chemotherapy with (MTX or intravenous systemic MTX should be added to
the treatment) [III, B]
• HDCT/ASCT, if feasible, should be the preferred treatment strategy in chemosensitive relapse [I, A]
Continued
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Table 8. Continued
PCNSLs
• Stereotactic biopsy is recommended as a minimal invasive technique to obtain a histopathological diagnosis [III, A]; therefore, resection of PCNSL
cannot be recommended
• Additionally, testicular ultrasound examination in elderly male patients is recommended [V, B]
• HD-MTX-based regimens, in combination with HD-ara-C, are recommended for induction treatment if possible based on patient age, PS and organ
function [I, A]
• HD-MTX-based treatment should be considered whenever possible in elderly patients [II, A]
• Intrathecal chemotherapy cannot be routinely recommended if appropriate systemic chemotherapy is applied and could be considered in the case of
severe meningeal involvement [IV, C]
• WBRT as consolidation after HD-MTX-based chemotherapy is still commonly applied in young patients and generally avoided in those >60 years, as the
risk of neurotoxicity (including cognitive deterioration) is particularly high in elderly patients [III, B]
• Consolidation RT should be avoided in elderly patients who achieved CR [III, B], while in those not reaching a CR, it is preferable to use lower doses of
WBRT (36 or 23.4 Gy) based on response [III, B]
• Whether RT can safely be omitted without compromising long-term outcome also in younger patients in CR remains controversial [III, C]
• HDCT/ASCT as consolidation treatment could be considered as an alternative in eligible patients [III, B]
• For salvage treatments, no standard protocol can be recommended. Fit patients should be considered for HDCT/ASCT [III, B]
• WBRT remains an important palliative treatment in PCNSL lymphoma for those unable to tolerate or relapsing after high-dose, CNS-penetrating
chemotherapy and not fit for further chemotherapy [III, B]
PBL
• Diagnostic biopsy is mandatory [IV, A]
• In the rare instance of patients who have undergone surgical excision, they should still be managed identically as recommended below [V, B]
• Incorporation of rituximab should be routinely included in front-line chemoimmunotherapy as part of R-CHOP q 21d [III, B]
• The recommended treatment is 6 cycles of R-CHOP [III, A], followed by consolidative whole ipsilateral breast RT (30–36 Gy) [III, B]
• More aggressive or dose-escalated regimens as part of primary therapy are not indicated [III, B]
• CNS-directed prophylaxis should be considered for individual patients [III, B], it is recommended in high-risk patients, i.e. bilateral involvement [III, A]
• Patients with bilateral breast involvement represent a particularly high-risk group, and investigation of more intensive chemotherapy regimens in the
context of clinical trials is justified in such cases [IV, C]
• After relapse, the management strategy should be as for other instances of relapsed DLBCL, with reinduction chemoimmunotherapy aiming to proceed
to HDCT/ASCT, where feasible, in patients with responsive disease [IV, B]
PBoL
• R-CHOP ± consolidation RT (30–40 Gy) remains the standard approach for the patients with any stage of DLBCL with bone involvement [III, B]
• CNS prophylaxis is not routinely required in these patients [III, B]; however, an accurate assessment (CSF flow cytometry and brain MRI) and
prophylaxis can be recommended in patients with involvement of anatomic areas in close apposition to the CNS (skull and/or spine) [III, B]
• Patients with a pathological fracture should be initially managed similarly to standard PBoL. Consolidation RT (30–40 Gy) to the fractured bone may be
given [IV, C]
• Initial surgery should be considered only if chemotherapy delays can be avoided [IV, C]
New treatments such as HDCT/ASCT or alternative chemoimmunotherapy are only recommended in the case of biopsy-proven persisting disease or clear
clinical or radiological progression [III, A]
DLBCL, diffuse large B-cell lymphoma; IPI, international prognostic index; aaIPI, age-adapted IPI; PMBCLs, primary mediastinal large B-cell lymphomas;
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone; R-VACOP-B; rituximab, etoposide, doxorubicin, cyclophosphamide,
vincristine, prednisolone, bleomycin; R-MACOP-B, rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, bleomycin; R-
CHOP14, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone every 14 days; DA-EPOCH-R, dose-adjusted etoposide, prednisone,
vincristine cyclophosphamide, doxorubicin and rituximab; RT, radiotherapy; CMR, complete metabolic response; HDCT/ASCT, high-dose chemotherapy
followed by autologous stem cell transplantation; CR, complete remission; FDG, fluorodeoxyglucose; PET/CT, positron emission tomography/computed
tomography; PTLs, primary testicular lymphomas; CNS, central nervous system; MTX, methotrexate; PCNSLs; primary central nervous system
lymphomas; HD-MTX, high-dose methotrexate; HD-ara-C, high-dose cytarabine; PS, performance status; WBRT, whole-brain radiotherapy; PBL, primary
diffuse large B-cell breast lymphoma of the breast; PBoL, primary diffuse large B-cell bone lymphoma of the bone; CSF, cerebral spinal fluid; MRI, magnetic
resonance imaging.
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